Post-marketing surveillance of AMYViD Injection

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031220067

Enrollment

500

Registered

2022-05-17

Start date

2020-03-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visualization of beta amyloid plaques in the brain of the patients with suspected mild cognitive imp

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received AMYViD Injection during the enrollment period of this study.

Exclusion criteria

Exclusion criteria: Patients who enrolled in other clinical studies or clinical trials during the enrollment period of this study.

Design outcomes

Primary

Measure	Time frame
Collect adverse events of AMYViD and confirm its safety. - Unknown adverse drug reactions (particularly important adverse drug reactions) - Factors that may affect safety, efficacy, etc. - Status of adverse drug reactions under actual use of drugs	—

Contacts

Public ContactManager of Potmarketing surveillane

PDRadiopharma Inc.

s-amyvid_gpsp@pdradiopharma.com+81-362630831

Outcome results